Market Research Report
Global Celiac Disease Drugs Market 2017-2021
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||522237|
|Published||Content info||76 Pages
Delivery time: 1-2 business days
|Global Celiac Disease Drugs Market 2017-2021|
|Published: June 28, 2017||Content info: 76 Pages||
Celiac disease is an autoimmune inflammatory disease of the small intestine, which is triggered by intake of gluten from wheat and other sources through our food. Presently, there is no specific drug approved for celiac disease, and the first line of treatment is completely dominated by a gluten-free diet. There are few anti-inflammatory and immunosuppressant drugs and nutritional supplements that are used as off-label therapy in celiac disease. All these off-label therapies are considered as second-line of treatment.
Technavio's analysts forecast the global celiac disease drugs market to grow at a CAGR of 24.22% during the period 2017-2021.
The report covers the present scenario and the growth prospects of the global celiac disease drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio's report, Global Celiac Disease Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.